Navigation Links
Neogen reports 19% increase in annual revenues
Date:7/22/2014

LANSING, Mich., July 22, 2014 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that revenues for its 2014 fiscal year, which ended May 31, increased 19% from the previous year to $247,405,000. Fiscal year net income was $28,158,000, compared to the prior year's $27,190,000. Adjusted for a 3-for-2 stock split effective Oct. 30, 2013, earnings per share in the current year were $0.76, compared to $0.75 a year ago. Both revenues and net income for the 2014 fiscal year established new all-time highs for the 32-year-old company.

Neogen's fourth quarter revenues were $67,262,000, a 20% increase over revenues from FY 2013's final quarter. Net income in the current fourth quarter was $7,537,000 compared to $7,032,000 in FY 2013, or $0.20 per share compared to $0.19 per share in FY 2013, when adjusted for the stock split.

The fourth quarter was the 89th quarter of the past 94 quarters that Neogen reported revenue increases as compared with the previous year — including all consecutive quarters in the last nine years.

"We are pleased to report another strong year for Neogen, especially in terms of revenue growth, operational strength, and increase in stockholders' equity," said James Herbert, Neogen's chief executive officer and chairman. "Our 23-year record of quarterly growth is a tradition our 900 plus employees are very proud of. Not only was this a good financial year, but we also made three acquisitions and developed a number of new products that will help position us to capitalize on growth opportunities in the markets we serve."

Neogen's gross margin was 49.6% of sales in its 2014 fiscal year, compared to 52.8% of sales for FY 2013. This decrease was due almost entirely to the change in the company's overall product mix. Total operating expenses, expressed as a percentage of total revenues, decreased to 32% in the 2014 fiscal ye
'/>"/>

SOURCE Neogen Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neogen COO resigns
2. Neogen licenses Cargill patents
3. Neogen acquires Chem-Tech
4. Neogen reports second quarter results
5. Neogen acquires Prima Tech
6. Neogen shares to be priced Oct. 31
7. Neogen shares begin post-split trading
8. Neogen reports 18% revenue increase
9. Neogen announces 1st quarter results conference call
10. Neogen launches comprehensive dairy heifer genomic test
11. Neogen announces Bohannon retirement, successor named
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... and RARITAN, N.J. , ... multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) ... investigational, human anti-CD38 monoclonal antibody – achieved an ... CI, 20.8-38.9), as assessed by an independent review ... The ORR was consistent among the pre-specified subgroups ...
(Date:5/29/2015)... Los Gatos, CA (PRWEB) May 29, 2015 ... diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that ... technology for same-shift bacterial detection and susceptibility testing ... asm2015 on May 31, 2015 in ... a new class of molecular diagnostics that can ...
(Date:5/29/2015)... 29, 2015 When a leading ... a request to design an industrial oven ... prescription medications being produced using a 3D-printing process, ... a robotic gantry, heat-saving windows, and internal actuators ... of 3D-printed pills to exact specifications. , To ...
(Date:5/29/2015)... WISCONSIN (PRWEB) May 29, 2015 Results ... virus talimogene laherparepvec and its ability to reduce the ... treatment have been published in the Journal of Clinical ... patients with stages IIIB, IIIC and IV melanoma, a ... of the study was to evaluate the safety and ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2
... DiversityInc, a leading publication on diversity and business, has recognized University Hospitals ... listing. , , , ... ranked the Top 50 Companies for Diversity based on results from an extensive questionnaire. ... , , ...
... Germany , June 15, 2010 Pieris AG,announced today the ... program, PRS-050, an anti-VEGF Anticalin. The trial is an,open-label, dose-escalating evaluation of ... sites in, Germany , the trial is underway and patients from the ... , ...
... ... upgraded SaaS application for the life sciences industry that incorporates distinctive features and ... ... new-media solutions for the life sciences industry, today announced the release of Version ...
Cached Biology Technology:Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation 2Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound 2Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 2Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 3
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... age to fly the nest, but it,s hormones that actually control ... University of Leeds. The study published online in ... main trigger which causes chicks to leave the nest and embark ... studying a colony of Manx Shearwaters ( Puffinus puffinus ), on ...
... One of cancer,s most frightening characteristics is its ability to ... cancer, including the skin cancer known as melanoma, tailored drugs ... only partial, temporary responses in patients. One of the burning ... remains: how does cancer evade drug treatment? New research ...
... you are a primate crossing the jungle. Using human street ... required to navigate a forest using different strategies and found ... was presented at the Society for Experimental Biology,s meeting in ... help us to understand why orangutans spend most of their ...
Cached Biology News:Hormones dictate when youngsters fly the nest, says new research 2Tumor microenvironment helps skin cancer cells resist drug treatment 2Tumor microenvironment helps skin cancer cells resist drug treatment 3Tumor microenvironment helps skin cancer cells resist drug treatment 4
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human Legumain Affinity Purified Polyclonal Ab...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: